🚀

eCTD v4.0 & the EU Impact: What’s New as of February 2026

The electronic Common Technical Document (eCTD) is the standard format used globally for submitting regulatory applications for medicines, biologics and related products. After years of development, the next generation — eCTD version 4.0 — is now entering real-world use and gradually reshaping the regulatory landscape.

While many regions are still in early stages of implementation, Europe is making important progress toward supporting eCTD v4.0 — especially for centralized marketing authorisation (CAP) dossiers — and sponsors need to understand what’s coming, why it matters, and how to prepare.

🧠 What Is eCTD v4.0 – At a Glance

eCTD v4.0 is the next major iteration of the electronic regulatory submission standard originally created by the International Council for Harmonisation (ICH). It modernises the way dossiers are created, organised and transmitted to health authorities around the world.

Key enhancements include:

Unified XML-based backbone and metadata for richer, more granular content tagging and lifecycle information.
Flexible document structure and controlled vocabulary that reduces reliance on rigid folder hierarchies and supports advanced document reuse.
Improved lifecycle management enabling better tracking, reuse and linking of regulatory content across updates and applications.
Future potential for two-way communication between sponsors and regulators (though this is not yet widely implemented).

Think of v4.0 as moving submissions from a digital filing cabinet into a smart, data-rich ecosystem that can better support agile reviews, cross-region harmonisation, and downstream lifecycle activities.

🇪🇺 EU Regulatory Status — What’s Happening Now (Early 2026)

1. Optional eCTD v4.0 Use Started for EU CAP MAAs

As of late December 2025 and into early 2026, the European Medicines Agency (EMA) has enabled optional use of eCTD v4.0 for centralised marketing authorisation applications (MAAs).

This means that:

Sponsors may submit new MAA dossiers in eCTD v4.0 format even though it is not yet mandatory.
The traditional eCTD v3.x format continues to be accepted during this transition period.
Applicants are advised to contact the EMA eCTD v4.0 team prior to submission to ensure support and coordination.

This optional period is designed to let sponsors gain experience, test tools and workflows, and work with regulators in a controlled way before full adoption.

2. Forward Compatibility Pilot Coming in 2026

EMA has announced plans to launch Pilot Phase 3 on Forward Compatibility for CAPs in 2026— a major step toward long-term implementation.

Forward compatibility means that:

eCTD v4.0 packages will be structured such that they can be forward-linked to future review cycles and modules.
Tools and agency systems will be exercised and validated using real sponsor content.

Official participation details and timelines are expected to be published in Q1 2026, after which companies will be able to engage more directly with the pilot.

3. EU Validation Criteria Under Review

EMA updated its eCTD v4.0 validation criteria and sought public comments through end of December 2025.

These validation rules define the technical checks used to ensure submissions conform to EU M1 (regional) and global standards — and updating them is critical for robust acceptance of eCTD v4.0 packages.

A finalized validation scheme is expected to underpin broader acceptance as the pilot evolves.

📊 How the EU Timeline Fits Globally

European eCTD v4.0 implementation is part of a broader global rollout that varies by region:

Japan’s PMDA expects to make v4.0 mandatory by April 2026, having already supported operational submissions.
The U.S. FDA has accepted optional v4.0 submissions since September 2024; mandatory timelines are projected toward the end of the decade.
Many regions, including Europe, are staging their adoption with pilots, optional phases, and future mandatory switches.

This global mosaic underscores the need for multi-region preparation strategies that accommodate staggered deadlines and differing rules.

🛠 What Sponsors Need to Do Now

If your organisation is preparing for eCTD v4.0 submissions in Europe, here are key practical steps for 2026:

✅ 1. Upgrade Publishing Tools & Systems

Ensure your eCTD publishing software supports the new HL7 RPS-based structures and controlled vocabularies required for v4.0.

✅ 2. Train Regulatory & Submission Teams

eCTD v4.0 involves new concepts such as context of use, metadata tagging, and lifecycle management — teams must be familiar with them.

✅ 3. Participate in the EMA Pilot

Engaging with the forward compatibility pilot will accelerate learning and reveal technical issues early.

✅ 4. Work with Vendors & Consultants

Coordinate with vendors and regulators to troubleshoot any tool gaps, validation problems, or workflow challenges.

✅ 5. Monitor EMA Updates Closely

Regulatory guidance, validation criteria and timelines continue to evolve — staying informed is essential.

🎯 Why eCTD v4.0 Matters for Pharma Regulation

The shift to eCTD v4.0 is not just a file format change — it represents a strategic evolution in regulatory submissions:

💡 Better document reuse — reduce duplication and simplify lifecycle updates.
💡 Richer data capabilities — structured metadata improves discoverability and review efficiency.
💡 Global alignment — harmonized submissions across major markets accelerate regulatory pathways.
💡 Future-ready submissions — positioning sponsors for advanced functionalities like automated review tools or smart analytics.

In a world where regulatory agencies handle ever-growing volumes of complex data, the more flexible, data-centric eCTD v4.0 provides the foundation for the next generation of digital regulatory review. This phased, consultative approach gives sponsors time to prepare, test and adapt — but early engagement, tool readiness and team training will define success in the transition to eCTD v4.0.

At Regvista, we remain committed to support biopharmaceutical leaders navigating their transformative journey—bringing cutting-edge therapies to market faster and safer. Please feel free to contact us by submitting your enquiry to deployment@regvista.co.uk

🚀